证券记录 · 已归档季度
TVTX
Travere Therapeutics, Inc. · Healthcare · Biotechnology
13被追踪持有人
n/aΔ持有人
10.32M持有股份
$84.85M报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.17M | $68.91M | n/a | n/a |
| Q2 2026 | 114 | +17 | 68.21M | $3.64B | +21 | −4 |
| Q1 2026 | 100 | -5 | 69.82M | $2.07B | +9 | −14 |
| Q4 2025 | 104 | +1 | 74.66M | $2.85B | +1 | n/a |
| Q3 2025 | 21 | +1 | 36.01M | $860.71M | +2 | −2 |
| Q2 2025 | 18 | +1 | 30.33M | $448.83M | +2 | −1 |
| Q1 2025 | 14 | 0 | 16.78M | $300.70M | n/a | n/a |
| Q4 2024 | 14 | +1 | 16.09M | $280.22M | +2 | −1 |
| Q3 2024 | 12 | -1 | 7.80M | $109.09M | +1 | −2 |
| Q2 2024 | 13 | n/a | 10.32M | $84.85M | n/a | n/a |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 2.95M | n/a | $24.24M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 2.20M | n/a | $18.12M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (被动) | 1.67M | n/a | $13.70M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | D. E. Shaw & Co. ✦ | 1.53M | n/a | $12.60M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 640.31K | n/a | $5.26M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Adage Capital Partners ✦ | 400.00K | n/a | $3.29M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 320.58K | n/a | $2.64M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 314.18K | n/a | $2.58M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 74.07K | n/a | $608,848 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Wellington Management ✦ | 72.66K | n/a | $597,249 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | Norges Bank ✦ (被动) | 71.00K | n/a | $583,620 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Fisher Asset Management ✦ | 43.18K | n/a | $354,956 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 33.44K | n/a | $275,000 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1 持有人, 121.20K 股份, $3,600 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 15
Dube Eric M
Officer, Director · 78.40K 股 · $4.31M
Oct 15
Dube Eric M
Officer, Director · 37.27K 股 · $2.02M
Oct 15
Dube Eric M
Officer, Director · 128.06K 股 · $6.78M
Sep 17
Heerma Peter
Officer · 8.28K 股 · $538,917
Sep 17
Dube Eric M
Officer, Director · 101.69K 股 · $6.57M
Sep 17
Dube Eric M
Officer, Director · 6.80K 股 · $441,795
Sep 16
Dube Eric M
Officer, Director · 99.72K 股 · $6.31M
Sep 16
Heerma Peter
Officer · 79.11K 股 · $5.04M
Sep 16
Heerma Peter
Officer · 93.60K 股 · $5.92M
Sep 16
Dube Eric M
Officer, Director · 96.12K 股 · $6.12M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 14
SC 13G/A: ARMISTICE CAPITAL, LLC
Aug 12
SC 13G: BANK OF AMERICA CORP /DE/
Aug 07
SC 13G: STATE STREET CORP
Aug 06
SC 13G/A: FMR LLC
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据